I t’s now almost a decade since Sandoz launched the first atypical antipsychotic (clozapine) in the UK and opened a new chapter in the history of schizophrenia management. A number of other atypicals followed. These undoubtedly offer clinical benefits in this devastating disease, especially for patients who either cannot tolerate, or do not respond to, older agents.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
About this article
Cite this article
Greener, M. Clinicians in two minds over atypical antipsychotics. Pharmacoecon. Outcomes News 227, 3–4 (1999). https://doi.org/10.1007/BF03294168
- National Health Service